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ABSTRACT 22 
In skeletal muscle, an accumulation of lipid droplets (LDs) in the subsarcolemmal space is 23 
associated with insulin resistance, but the underlying mechanism is not clear. We aimed to 24 
investigate how the size, number and location of LDs are associated with insulin sensitivity and 25 
muscle fiber types, and are regulated by aerobic training and treatment with an erythropoiesis-26 
stimulating agent (ESA) in healthy young untrained males. LD analyses were performed by 27 
quantitative transmission electron microscopy and insulin sensitivity was assessed by a 28 
hyperinsulinemic euglycemic clamp. At baseline, we found that only the diameter (and not the 29 
number) of individual subsarcolemmal LDs was negatively associated with insulin sensitivity (R
2
 = 30 
0.20, P = 0.03, n = 29). Despite 34% (P = 0.004) fewer LDs, the diameter of individual 31 
subsarcolemmal LDs was 20% (P = 0.0004) larger in type 2 fibers than in type 1 fibers. 32 
Furthermore, aerobic training decreased the size of subsarcolemmal LDs in the type 2fibers, and 33 
ESA treatment lowered the number of both intermyofibrillar and subsarcolemmal LDs in the type 34 
1fibers. In conclusion, the size of individual subsarcolemmal LDs may be involved in the 35 
mechanism by which LDs are associated with insulin resistance in skeletal muscle. 36 
KEYWORDS: Intramuscular lipid droplets; insulin sensitivity, transmission electron microscopy; 37 
skeletal muscle fiber types, aerobic training, eryhropoietin.  38 
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INTRODUCTION 39 
In skeletal muscle, accumulation of lipid droplets (LDs) is associated with insulin resistance (15, 40 
37). However, a mechanism linking LDs with insulin resistance is still lacking. 41 
LDs are distributed in between the myofibrils (intermyofibrillar LDs) and just beneath the surface 42 
membrane (subsarcolemmal LDs). Several studies have suggested that only the subsarcolemmal 43 
LDs are associated with insulin resistance in humans (3, 9, 28, 35). However a causal relationship 44 
has been questioned by the lack of association after aerobic training (35), and by the fact that white 45 
rat muscles (type 2 fibers) were devoid of subsarcolemmal LDs despite being insulin-resistant (24). 46 
Interestingly, the individual size of LDs has been measured in a few studies. He and colleagues 47 
found an association between changes in LD size and insulin sensitivity after weight loss and 48 
physical activity (17), but several other studies have found no changes in LD size following 49 
training, exercise, or dietary interventions using immunofluorescent staining (11, 23, 31, 45). 50 
However, analyses of the subsarcolemmal region by transmission electron microscopy have 51 
revealed larger subsarcolemmal LDs in old individuals than in young individuals (9), and an 52 
increase in the size of subsarcolemmal LDs after acute exercise in old overweight men (3). 53 
Therefore, a comprehensive understanding of the role of LDs in skeletal muscle requires detailed 54 
analyses of LD size and subcellular distribution. 55 
Aerobic training mediates improved fat oxidative capacity and improved insulin sensitivity (12). On 56 
the other hand, erythropoietin treatment also tends to increase fat oxidation capacity in humans (8), 57 
but with no effects on insulin sensitivity (6). Therefore, a comparison of the effects aerobic training 58 
with the effects of erythropoietin-treatment has the potential to separately delineate which aspects 59 
of fat metabolism that are related to insulin sensitivity. In the present study, we aimed to investigate 60 
the association between insulin sensitivity and the LD size, number, and subcellular distribution in 61 
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the skeletal muscle of untrained men, and, secondly, the effect of aerobic training and/or 62 
erythropoiesis-stimulating agent (ESA) treatment on the LD size, number, and subcellular 63 
distribution of different skeletal muscle fiber types in untrained men. We hypothesized that the size 64 
of subsarcolemmal LDs would be negatively associated with insulin sensitivity, and that aerobic 65 
training would decrease the size of subsarcolemmal LDs.  66 
MATERIALS AND METHODS 67 
Subjects 68 
This study is part of a larger study with several published companion papers (4, 5, 6, 7, 20, 26, 33, 69 
42), of which three papers address the effect of training and/or ESA treatment on metabolic 70 
parameters (6, 26, 33). Thirty-seven healthy, untrained men, all non-smokers, were included in this 71 
part of the study after receiving oral and written information, and after giving written informed 72 
consent to participate, in accordance with the Declaration of Helsinki. The study was approved by 73 
the Local Human Ethical Committee of Central Denmark Region (M-20110035), and was 74 
registered at www.clinicaltrials.gov with the clinical trial number NCT01320449. 75 
Each participant underwent a physical examination and electrocardiogram measurements. 76 
Inclusion criteria included: age between 18 and 35 years, body mass index (BMI) between 18 and 77 
29 kg/m
2
, normal blood pressure < 135/85 mmHg, hematocrit < 45%, and maximal oxygen uptake 78 
(?̇?O2 max) < 50 ml/min/kg, 79 
Experimental design 80 
In a parallel design, the subjects were randomized into four experimental groups: 1) sedentary and 81 
placebo treatment (SP, n = 9), 2) sedentary and ESA treatment (SE, n = 9), 3) endurance training 82 
and placebo treatment (TP, n = 10) and 4) endurance training and ESA treatment (TE, n = 9). 83 
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The subjects were treated in a single-blinded manner with either ESA (Darbepoietin-α, Aranesp, 84 
Amgen, Thousand Oaks, CA, USA) or placebo for 10 weeks. ESA was administered 85 
subcutaneously once weekly with a dose of 40 μg for the first 3 weeks and 20 μg for the remaining 86 
7 weeks. The subjects were supplemented with 100 mg iron orally/day (Ferrous sulfate, Ferro 87 
Duretter, GlaxoSmithKline, Brentford, UK) from one week before the treatment until the end of the 88 
study.  89 
Endurance training was supervised and consisted of biking on an indoor ergometer. The subjects 90 
performed three training sessions per week; each training session consisted of 5 min warm up, a 91 
main set and 5 min cool down. Each of these three main sets was performed once weekly: 1) 40 92 
min, 2) 2 x 20 min (5 min easy biking in-between), and 3) 8 x 5 min (1 min easy biking in 93 
between). All sets were performed with the maximal amount of watts possible, on average 65% of 94 
maximal workloads. The last training session was performed ~60 h before the post-tests after 10 95 
weeks of training, in order to avoid any potential acute exercise effects. During the 10-week study 96 
period, the participants were informed not to change their level of physical activity or their dietary 97 
habits. 98 
On experimental days, before and after the 10 week intervention period, the subjects arrived at the 99 
clinical research unit by taxi after an overnight fast (water intake was allowed). The participants 100 
were instructed to refrain from physical activity, alcohol intake or dietary changes for 3 days prior 101 
to the experimental day. No standard meals were provided before the experimental days. Two 102 
intravenous catheters were inserted: one in the antecubital vein for infusion and one in a heated 103 
dorsal hand vein for sampling of arteialized blood. A hyperinsulinemic euglycemic clamp was 104 
performed to assess insulin sensitivity. Blood was collected before the start of the experiment 105 
(fasting condition) and at the end of the basal and clamp period as previously described (6). A 106 
biopsy was obtained from the vastus lateralis using a Bergström needle with suction under local 107 
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anaesthesia with lidocain (20 mg/ml). The same skilled physician collected all biopsies. Each 108 
biopsy was divided into several muscle segments for multiple purposes. Due to poor compliance (n 109 
= 1) and lack of tissue (n = 10) the biopsy material fixed with glutaraldehyde in 0.1M sodium 110 
cacodylate buffer (pH 7.3) for transmission electron microscopy consisted of 63 samples distributed 111 
within the experimental groups as follows: 6 and 9 (SP), 7 and 8 (SE), 8 and 10 (TP), and 8 and 7 112 
(TE), before and after the intervention, respectively. In the four groups the number of paired 113 
samples was respectively 6, 6, 8 and 6.  114 
Blood analysis 115 
Fasting insulin levels were measured by a commercial time-resolved immunoflourometric assay 116 
(Auto DELFIA; PerkinElmer, Turku, Finland). Fasting plasma glucose was measured immediately 117 
after collection on an YSI 2700 Select (YSI Life Sciences, Yellow Springs OH). Fasting free fatty 118 
acids (FFA) were analyzed by a commercially available kit (Wako Chemicals, Neuss, Germany). 119 
Serium high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol and triglyceride 120 
were measured in a Cobas 6000 (Roche Applied Sciences). 121 
Hyperinsulinemic euglycemic clamp 122 
A hyperinsulinemic euglycemic clamp was performed to assess insulin sensitivity. Two intravenous 123 
catheters were inserted: one in the antecubital vein for infusions and one in a heated dorsal hand 124 
vein for sampling of arterialized blood. Blood was collected before the start of the experiment (t = 0 125 
min) and at the end of the basal (t = 240 min) and clamp period (t = 360 min). Blood samples were 126 
centrifuged for 10 min at 4
o
C and 3800 rpm, and stored at minimum -20
o
C.  127 
Insulin was infused from t = 240-360 min (0.6 mU/kg/min; Actrapid, Novo Nordisk A/S, 128 
Bagsværd, Denmark). Plasma glucose was clamped at ~5 mmol/L by adjusting the intravenous 129 
infusion rate of 20% glucose according to plasma glucose measurements every 10 min. Insulin 130 
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sensitivity (M-value) was estimated from the glucose infusion rate (GIR, mg/min):  M-value 131 
(mg/kg/min) = GIR / total body weight. The amount of infused glucose required to maintain blood 132 
glucose at ~5 mmol/L during the clamp, i.e. M-value, reflects the peripheral insulin sensitivity. 133 
Transmission electron microscopy 134 
Muscle specimens were prepared for transmission electron microscopy as described previously 135 
(35). In order to obtain a high number of fibers per muscle specimen, the ultra-thin sections were 136 
cut in three depths separated by 150 µm (using a Leica Ultracut UCT ultramicrotome). After the 137 
sections were contrasted with uranyl acetate and lead citrate, they were examined in a pre-calibrated 138 
transmission electron microscope (Philips EM 208, Philips, Amsterdam, The Netherlands) and a 139 
Megaview III FW camera (Olympus, Soft Imaging Solutions GmbH, Münster, Germany), or a 140 
Philips CM100 (Philips, Amsterdam, The Netherlands) and an Olympus Veleta camera (Olympus, 141 
Soft Imaging Solutions GmbH, Münster, Germany). From each fiber, images were obtained at x10-142 
13,000 magnification (Fig. 1A-B). We obtained as many images as possible, or a maximum of 32 143 
images of the subsarcolemmal space (20 (13:24)) and a maximum of 24 images of the myofibrillar 144 
space (12 (9:15)).  145 
Fibers were defined as type 1 or 2, based on a combination of intermyofibrillar mitochondria 146 
volume and Z-disc thickness as previously described (34, 43). In brief, intermyofibrillar 147 
mitochondrial volume fraction was plotted against Z-disc thickness for all the fibers (n = 4–12) 148 
obtained from each biopsy. For each biopsy, the fibers with the highest intermyofibrillar 149 
mitochondrial volume fraction and thickest Z-disc were classified as type 1 fibers and vice versa for 150 
type 2 fibers. In order to identify the two main fiber types, all intermediate fibers were discarded 151 
and only distinct type 1 and 2 fibers were included (n =2–3 fibers of each type per biopsy). The 152 
defined type 1 fibers had a higher volume of intermyofibrillar mitochondria per myofibrillar volume 153 
than type 2 fibers (7.0 (5.6-8.8) vs 3.9 (2.7-5.3) µm
3
 µm
-3
 10
2
, P < 0.0001), and a higher volume of 154 
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subsarcolemmal mitochondria per muscle surface than type 2 fibers (15.3 (8.5-25.8) vs 6.9 (3.4-155 
12.1) µm
3
 µm
-2
 10
2
, P < 0.0001), and a thicker Z-disc than type 2 fibers (77 (69-83) vs 70 (65-74) 156 
nm, P = 0.0001). 157 
The intermyofibrillar LD volume per myofibrillar volume (VV(IL)) was estimated by point counting 158 
according to the principle of Cavalieri (46) using the formula AA(IL) = VV(IL), where AA(IL) is the 159 
myofibrillar area fraction of intermyofibrillar LDs. The AA(IL) is estimated by point counting (46) 160 
using a grid size of 135 nm. In order to take into account the cylindrical shape of the fiber, the 161 
superficial images were weighted three times higher than the central images.  162 
The subsarcolemmal LD volume per muscle surface was also estimated by point counting according 163 
to the principle of Cavalieri (46) and expressed relative to the surface area of the fiber: AA(SL) / SA = 164 
VV(SL) / SA, where AA(SL) is the area fraction of subsarcolemmal LDs, SA is the fiber surface area 165 
(µm
2
) and VV (SL) is the myofibrillar volume fraction of subsarcolemmal LDs. The AA(SL) is 166 
estimated by point counting (46) using a grid size of 135 nm, and SA calculated as the length of the 167 
fiber multiplied by the thickness of the image (60 nm). 168 
A coefficient of error (estCE) for the intermyofibrillar and subsarcolemmal LD volumes was 169 
calculated as proposed for stereological ratio-estimates by Howard & Reed (22). 170 
The average of the shortest and longest diameter of the LDs was determined by direct length 171 
measurements using iTEM. In each biopsy, a total of 54 (30:59) and 21 (8:35) intermyofibrillar LDs 172 
were measured per fiber type 1 and 2, respectively, and in the subsarcolemmal space the 173 
corresponding numbers were 18 (11:35) and 14 (6:20) per fiber type 1 and 2, respectively. The 174 
number of LDs was calculated by dividing the volume fractions of LDs by the average volume of 175 
individual LDs. LDs were assumed to be spherical. 176 
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When the distribution of intermyofibrillar and subsarcolemmal LD volume is expressed relative to 177 
the total content, the fibers were assumed to be of cylindrical shape with a diameter of 80 μm. Since 178 
intermyofibrillar LD volume is expressed as a volume density and subsarcolemmal LD volume as 179 
volume per fiber surface area, total values were obtained by recalculating the subsarcolemmal LD 180 
volume to a volume density by the formula: volume beneath the surface area of a cylindrically 181 
shaped fiber (Vb) = R × 0.5 × A, where R is fiber radius and A is the fiber surface area. 182 
 183 
All the analyses were conducted by two blinded investigators (JN and AEC), where the images 184 
from the different groups, time points, and fiber types were distributed equally between 185 
investigators. Inter-investigator variability in detecting the presence of LDs was tested on 558 186 
images, where both investigators assessed the number of lipids droplets on each image. This 187 
showed an agreement of 85% and a Kappa-score of 0.71 (CI: 0.68:0.77), which is regarded as a 188 
good agreement between the investigators (1, 25).  189 
Statistics and data treatment 190 
Statistical analyses were performed using Stata 13.1 (StataCorp. 2013; Stata Statistical Software: 191 
Release 13; StataCorp LP, College Station, TX, USA). All interactions or main effects were tested 192 
using a linear mixed-effects model, with subjects and time as random effects and with time, ESA 193 
treatment and training as fixed effects. Variables were log or square-root-transformed before 194 
analysis, and the assumption of normal distribution was tested by the Shapiro-Wilk W test and the 195 
assumption of heteroscedasticity was tested by the Cook-Weisberg test. Interactions or main effects 196 
were tested by a Wald test. Post-estimations were performed for point estimates, p-values and 197 
confidence intervals for linear combinations of coefficients.  Correlation analyses were performed 198 
by Pearson’s correlation coefficient with Bonferonni-corrected P-values for multiple testing (i.e. 199 
intermyofibrillar vs. subsarcolemmal lipids and size vs. number of LDs). All box and whisker plots 200 
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are medians, interquartile range (IQR) and adjacent values.  Significance level was set at α = 0.05. 201 
Assuming a coefficient of variation (SD/mean) of 0.23 for both intermyofibrillar and 202 
subsarcolemmal lipid droplet volumes of each fiber type within each group (35), power analyses 203 
showed that 29 subjects would result in 80% power to detect a 12% difference between fiber types 204 
at baseline, and 9 subjects per group would result in 80% power to detect a 25% difference from pre 205 
to post the different interventions. 206 
RESULTS 207 
Study participants 208 
There were no significant differences in anthropometric characteristics between the four 209 
experimental groups, except for a small difference in mean age (Table 1). 210 
Precision of estimates of volume fractions and size of LDs 211 
The medians (IQR) estCE of intermyofibrillar LD volume fraction were 0.17 (0.14-0.22) and 0.27 212 
(0.21-0.38) in type 1 and 2 fibers, respectively. The median estCE of subsarcolemmal LD volume 213 
fraction were 0.29 (0.23-0.35) and 0.33 (0.26-0.46) in type 1 and 2 fibers, respectively. No further 214 
decrease in estCE of the volume fraction of intermyofibrillar and subsarcolemmal LD was achieved 215 
after analyzing 2500 µm
2
 of the myofibrillar region  (Fig. 1C) and 400 µm of the fiber length (Fig. 216 
1D), respectively. The percentage change in mean droplet diameter for each increase in number of 217 
droplets was found to be < 2% after measurement of 20 droplets of both the intermyofibrillar and 218 
subsarcolemmal spaces. 219 
Association of size and number of LDs with insulin sensitivity 220 
As described in a companion paper, insulin sensitivity was improved after training, but not affected 221 
by ESA treatment (6). Investigation of the association of LDs with insulin sensitivity revealed an 222 
inverse relationship between the M-value and the volume of subsarcolemmal LDs per muscle 223 
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surface (R
2
 = 0.25, P = 0.01; Fig. 2A), and that this could be explained by an association between 224 
the M-value and the size of individual subsarcolemmal LDs (R
2
 = 0.20, P = 0.03; Fig. 2B), but not 225 
the number of subsarcolemmal LDs (R
2
 = 0.01, P = 1.00; Fig. 2C). Conversely, insulin sensitivity 226 
was not associated with either intermyofibrillar LD volume (R
2
 = 0.13, P = 0.11) or size (R
2
 = 0.03, 227 
P = 0.68), or the number of individual intermyofibrillar LDs (R
2
 = 0.14, P = 0.10). Similar findings 228 
were found if the M-value was corrected for differences in the serum insulin levels as described 229 
elsewhere (6).  230 
LDs in human muscle fiber types 231 
While the type 1 fibers had a higher (134%, P < 0.0001) volume fraction of intermyofibrillar LDs 232 
than the type 2 fibers (Fig. 3A), the volume fraction of subsarcolemmal LDs was not different 233 
between the two fiber types (P = 0.53; Fig. 3B). Consequently, the type 2 fibers had a higher 234 
relative contribution of subsarcolemmal LDs to total LDs than type 1 fibers (13% (6:22) vs. 6% 235 
(3:9), respectively, P = 0.0002). A discrimination between the size and number of individual LDs 236 
showed that the subsarcolemmal LDs in type 2 fibers had a 20% larger diameter than found in type 237 
1 fibers (611 vs 508 nm, respectively; P = 0.0004; Figs. 3D & 4B), whereas no difference was 238 
found in the size of intermyofibrillar LDs between type 2 and 1 fibers (512 vs 561 nm, respectively; 239 
P = 0.21, Figs. 3C & 4A). On the other hand, type 1 fibers had a higher number of LDs than type 2 240 
fibers in both the intermyofibrillar (97%; 8.4 vs 4.3 µm
-3
 10
3
, respectively; P < 0.0001; Fig. 3E) and 241 
subsarcolemmal region (57%; 20.4 vs 13.0 µm
-2
 10
3
, respectively; P = 0.004; Fig. 3F). The size 242 
distribution of intermyofibrillar LDs revealed right-skewed distributions ranging from 200 to 1400 243 
nm with a typical size of 500 nm, and that no distinct size classes existed in either type 1 or 2 fibers 244 
(Fig. 4A). A more complex distribution was found in subsarcolemmal LDs, showing an 245 
approximately right-skewed distribution also ranging from 200 to 1400 nm, but with a plateau 246 
(defined as 4 successive bins with comparable percentage after the first peak) between 400 and 600 247 
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nm in both type 1 and 2 fibers (Fig. 4B). The plateau indicated a combination of two or more size 248 
classes of LDs in the subsarcolemmal space (Fig. 4B). 249 
Effects of endurance training alone or in combination with ESA treatment 250 
There were no significant effects of training, ESA treatment, or a combination of training and ESA 251 
treatment, on the volume fraction of intermyofibrillar or subsarcolemmal LDs in type 1 fibers or 252 
type 2 fibers (Fig. 5A-D).  253 
However, the relative contribution of the volume fraction of intermyofibrillar LDs to total cellular 254 
volume fraction of lipid droplets increased in type 1 fibers (P = 0.002, Fig. 5E), while this did not 255 
reach statistical significance in type 2 fibers (P = 0.12, Fig. 5F). 256 
Training mediated a decrease of the diameter of subsarcolemmal LDs in type 2 fibers (22%, P = 257 
0.01, Figs. 6D & 7B), while this did not reach statistical significance in type 1 fibers (P = 0.15, Fig. 258 
6C & 7A). There were no significant effects of ESA treatment or a combination of training and 259 
ESA treatment on the size of individual subsarcolemmal LDs in type 1 fibers (Fig. 6C) or type 2 260 
fibers (Fig. 6D). Furthermore, there were no significantly effects of training, ESA treatment, or a 261 
combination of training and ESA treatment, on the size of individual intermyofibrillar LDs in type 1 262 
fibers (Fig. 6A) or type 2 fibers (Fig. 6B).  263 
The size distribution of intermyofibrillar LDs was not different after training than before training 264 
(Figs. 7A & 7C). However, the plateau observed between 400 and 600 nm of subsarcolemmal LDs 265 
in both fiber types before training became narrower (400-500 nm) after training (Figs. 7B & 7D). 266 
Neither training alone, nor in combination with ESA treatment, influenced the number of individual 267 
LDs in the intermyofibrillar or subsarcolemmal spaces of type 1 or 2 fibers (Fig. 6E-H). However, 268 
compared with placebo, the ESA treatment mediated a decrease in the number of both 269 
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intermyofibrillar (45%, P = 0.02; Fig. 6E) and subsarcolemmal LDs (61%, P = 0.05; Fig. 6G) in 270 
type 1 fibers. This effect of ESA treatment was not found in type 2 fibers (Figs. 6F and 6H). 271 
There were no correlations between the training-induced change in insulin sensitivity and the 272 
changes in subsarcolemmal or intermyofibrillar lipid droplets size (P = 0.54 and P = 0.53, 273 
respectively) or number (P = 0.78 and P = 0.90, respectively). 274 
DISCUSSION 275 
LD accumulation in skeletal muscle is closely linked to insulin resistance (e.g. 15, 16, 27, 37) and 276 
recent studies suggest that an accumulation of LDs specifically in the subsarcolemmal location is 277 
detrimental for insulin sensitivity compared to LDs in the intermyofibrillar location (3, 9, 28, 35). 278 
However, the underlying mechanism remains to be elucidated. Here we show, by quantitative 279 
transmission electron microscopy, that the size (and not the number) of individual subsarcolemmal 280 
LDs is negatively associated with insulin sensitivity in lean untrained men, suggesting a role of the 281 
size of individual LDs in the pathogenesis of skeletal muscle insulin resistance.  282 
Recently, it was shown that sedentary obese old individuals have more and larger subsarcolemmal 283 
LDs than lean old and young individuals, and that the subsarcolemmal LDs accumulated in 284 
response to acute exercise (3). Therefore, the subsarcolemmal region could potentially be the site 285 
for storage of excess FA supply to the muscle. At the whole cell level, a correlation between 286 
changes in LD size and insulin sensitivity has been found (17), but also that the size of LDs did not 287 
differ between endurance trained athletes and type 2 diabetic patients (45). 288 
Today, very little is known about the role of LD size in various cell types (47) and in particular it 289 
remains almost completely unknown in mammalian skeletal muscle (2). Small LDs with a high 290 
surface to volume ratio may be advantageous for rapid mobilization and turnover, whereas large 291 
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droplets may be a result of a storage function (32). Intriguingly, the size distribution of 292 
subsarcolemmal LDs with a plateau between 400 and 600 nm (Fig. 4B). This plateau could be the 293 
consequence of two normal distributions merged together, which indicates that there exists two or 294 
more subclasses of subsarcolemmal LD sizes. Recently, in an epithelia cell line, isolation of LDs of 295 
different sizes showed some common characteristics, but also differential composition and ability to 296 
interact with proteins (48), indicating independent functions of different LDs. 297 
We show that type 1 fibers have a ~ 2-fold higher number of equal-sized LDs in the 298 
intermyofibrillar space compared with type 2 fibers (Fig. 3). Since the intermyofibrillar LDs 299 
constitute 80-95% of the total cellular LD volume fraction (Fig. 3E-F), this is in accordance with 300 
previous studies on the total volumetric content of LD in skeletal muscle (40, 41, 45). However, in 301 
the subsarcolemmal space the volume fraction of LDs is not different between the two fiber types. It 302 
is, however, organized differentially, as characterized by a higher number and smaller LDs in type 1 303 
fibers than in type 2 fibers. Since we found an inverse association between subsarcolemmal LD size 304 
and insulin sensitivity at the whole muscle level (Fig. 2), the finding of larger subsarcolemmal LDs 305 
in type 2 fibers indicates that the type 2 fibers are less insulin-sensitive than the type 1 fibers. This 306 
is in agreement with rat studies showing that oxidative fibers (MHC IIa) have larger insulin-307 
stimulated glucose uptake than glycolytic fibers (MHC IIb and MHC IIx) (18, 30), but it remains to 308 
be investigated in human skeletal muscle fibers. However, an association between insulin sensitivity 309 
and the percentage of oxidative fibers in human skeletal muscles has been reported (29), indicating 310 
a fiber type difference in insulin sensitivity also in human skeletal muscle.  311 
The current results demonstrate a re-organization of LDs in skeletal muscle following endurance 312 
training, as shown by a higher fraction of LDs located in the intermyofibrillar space (Fig. 5) and a 313 
lowering of the size of the individual LDs in the subsarcolemmal space (Figs. 6 and 7). The latter 314 
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finding is in line with recent results (3, 28, 35) and together with a concomitant improved insulin 315 
sensitivity in the present study (see 6), emphasizes a role of subsarcolemmal LDs in insulin-316 
mediated glucose uptake. In addition we have shown, based on the same biopsy material, that 317 
training increases the number of capillaries per fiber with no additional effects of erythropoietin 318 
treatment (26), and that training has no effect on VLDL-TG metabolism in these healthy lean men 319 
(33). Therefore, the relationship between capillarization and the regulation of individual LDs in the 320 
subsarcolemmal space would be interesting to investigate.   321 
In one of our companion papers, we have shown, based on the same biopsy material, that 322 
erythropoietin treatment increases resting metabolic rate and expression of the mitochondrial 323 
uncoupling protein UCP2 (6). Therefore, it is likely that this effect of erythropoietin on muscle is 324 
most pronounced in type 1 fibers, and hence this provides an explanation for the current finding that 325 
erythropoietin treatment decreases the number of LDs specifically in type 1 fibers (Fig 6). The 326 
lower efficiency of mitochondria with elevated UCP2 levels could mediate a higher demand for 327 
LDs as a fuel source.  328 
Methodological considerations 329 
The very high resolution of electron microscopy (< 2 nm) compared to other techniques makes it 330 
suitable for measuring the size and the subcellular location of individual LDs (10). The 331 
investigation of estCE in relation to the total area analyzed for intermyofibrillar LD volume revealed 332 
that a estCE value of  ~ 0.20 can be achieved with 2500 µm
2
 and that only minor improvements in 333 
the precision are likely with additional area analyzed (Fig. 1C). A lower precision of the 334 
subsarcolemmal lipid volume estimate was found reaching a estCE of ~ 0.30 after analysis of 400 335 
µm length of fiber (Fig. 1D). In a previous study (35), we achieved estCE values of 0.40-0.50 in a 336 
mix of fiber types based on a total area analyzed of 620 µm2 and 220 µm fiber length, and this fits 337 
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well with the data obtained in this study (Fig. 1C-D). The variation between the diameters of 338 
individual droplets indicates that at least 20 droplets should be measured in order to achieve a 339 
robust estimate of the mean LD size. 340 
The results of the intervention part of the study are limited by the low sample size (6-10 subjects in 341 
the various groups). Although the method was optimized in order to obtain a high precision per 342 
estimate per biopsy, we could not detect differences smaller than ~35% from baseline to post 343 
intervention due to the low sample size. In addition, since the sample size of paired measurements 344 
before and efter training was low (n = 14) and given that the error in the difference is larger than at 345 
baseline, the lack of correlations between the training-induced change in insulin sensitivity and 346 
changes in the size or number of LDs should be regarded as inconclusive. 347 
Since the TEM method used in the present study is stain-free, the identification of the LDs is based 348 
on morphology alone. LDs were identified by the criteria that a single membrane or a fussy border 349 
(accumulation of associated proteins) should be visible. Inclusions of membrane-like structures 350 
within the LDs were allowed, because LDs may contain cholesterol, which creates concentric layers 351 
(13). The size of the individual LDs may be influenced by the preparation technique for TEM. 352 
However, while the use of alcohol solvents in histochemical techniques for LD analysis has been 353 
shown to initiate fusion of lipid droplets (14), it may be prevented in TEM preparations where the 354 
tissue has been post-fixed with osmium tetroxide making the lipid molecules insoluble (38). The 355 
validity of the TEM estimated LD volume fractions is based on the strong correlation between TEM 356 
and 
1
H-MRS based estimates of LD volume fractions (21) and the decrease of TEM estimated LD 357 
volume fractions after prolonged exercise (3, 11, 36, 44). 358 
Concluding remarks 359 
17 
 
In conclusion, LDs of human male skeletal muscles show differential spatial organization in distinct 360 
morphological fiber types. The type 1 fibers have a high number of small LDs throughout the cell, 361 
whereas the type 2 fibers have low number of LDs throughout the cell, and large LDs in the 362 
subsarcolemmal space. Interestingly, only the size, not the number, of subsarcolemmal LDs is 363 
inversely associated with insulin sensitivity and the size of these subsarcolemmal droplets is 364 
decreased following endurance training. These results clearly suggest that further research in LD 365 
morphology and spatial organization is needed, in order to fully understand the role of lipid 366 
metabolism in insulin resistance and the metabolic syndrome. Research is needed to investigate 367 
whether those findings also extend to females. 368 
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TABLES 505 
Table 1. Age, weight, BMI and fasting blood parameters of participants 
 SP  SE  TP  TE 
 
Baseline  
(n = 6) 
10 weeks  
(n = 9)  
Baseline  
(n = 7) 
10 weeks 
 (n = 8)  
Baseline  
(n = 8) 
10 weeks  
(n = 10)  
Baseline  
(n = 8) 
10 weeks  
(n = 7) 
Age (years) 26 (6) 25 (5)  23 (3) 23 (3)  21 (2)* 21 (2)†  25 ± 5 26 (5) 
Weight (kg) 78.3 (10.2) 79.1 (8.9)  79.4 (8.0) 83.6 (11.1)  74.6 (6.8) 74.2 (8.4)  81.0 ± 16.6 77.6 (17.1) 
BMI (kg/m2) 24.2 (3.5) 24.0 (2.9)  23.0 (1.5) 23.9 (1.5)  22.3 (2.0) 22.2 (2.1)  24.3 ± 3.5 23.6 (3.3) 
Insulin (pmol/l) 51 (12) 47 (18)  39 (17) 54 (57)  38 (16) 46 (31)  52 (32) 48 (2) 
Glukose (mmol/l) 4.9 (0.4) 4.9 (0.3)  5.0 (0.3) 4.9 (0.3)  4.9 (0.3) 5.0 (0.3)  5.0 (0.3) 5.2 (0.4) 
FFA (mmol/l) 0.45 (0.11) 0.47 (0.12)  0.32 (0.14) 0.43 (0.19)
 ‡  0.61 (0.26) 0.48 (0.18)  0.44 (0.11) 0.47 (0.06)
 ‡ 
HDL (mmol/l) 1.2 (0.3) 1.2 (0.3)  1.2 (0.1) 1.2 (0.3)  1.3 (0.2) 1.2 (0.2)  1.0 (0.2) 1.1 (0.3) 
LDL (mmol/l) 2.2 (0.7) 2.1 (0.6)  2.8 (0.8) 2.5 (0.8)  2.5 (0.8) 2.4 (0.9)  2.9 (0.2) 2.6 (0.4) 
TG (mmol/l) 1.0 (0.2) 0.9 (0.4)  1.1 (0.5) 1.1 (0.7)  0.8 (0.3) 1.1 (0.4)  0.9 (0.2) 1.2 (0.4) 
Cholesterol (mmol/l) 3.9 (0.7) 3.7 (0.6)  4.5 (0.7) 4.2 (1.0)  4.1 (0.9) 4.1 (0.9)  4.3 (0.4) 4.2 (0.5) 
Values are means (SD). BMI, body mass index; FFA, free fatty acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, 
triglyceride. SP: sedentary-placebo, SE: sedentary-ESA, TP: training-placebo, TE: training-ESA. *, different from SP (P = 0.02) and TE (P = 
0.05). †, different from SP (P = 0.008) and TE (P = 0.006). ‡, different from baseline (P < 0.001).  
  506 
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FIGURE LEGENDS 507 
Figure 1. Morphometric analyses of human muscle fibers by electron microscopy. A: 508 
Intermyofibrillar LDs (black arrows) located between the myofibrils and also close to the 509 
mitochondria (white asterisk). B: Subsarcolemmal LDs (white arrow) located just beneath the 510 
sarcolemma close to the mitochondria (white asterisk). C: The estCE of the volume of 511 
intermyofibrillar LD per muscle volume is plotted against the area of 60 nm thick images analyzed. 512 
The solid lines represent the means and the dotted lines represent the 95% confidence intervals. D: 513 
The estCE of the volume of subsarcolemmal LD per muscle surface area is plotted against the length 514 
of 60 nm thick images analyzed. The solid lines represent the means and the dotted lines represent 515 
the 95% confidence intervals.   516 
Figure 2. Insulin sensitivity is negatively associated with the size of individual subsarcolemmal 517 
LDs. Insulin sensitivity is plotted against the MHC-weighted total volume fraction of 518 
subsarcolemmal LDs (A), the size of individual subsarcolemmal LDs (B) and the number of 519 
subsarcolemmal LDs (C). Lines represent linear fit. n = 29 subjects. 520 
Figure 3. LDs in human muscle fiber types at baseline. A: The volume fraction of 521 
intermyofibrillar LDs is higher in type 1 fibers than in type 2 fibers. B: No difference in the volume 522 
fraction of subsarcolemmal LDs between type 1 and 2 fibers. C: No difference in the diameter of 523 
intermyofibrillar LDs between type 1 and 2 fibers. D: The diameter of subsarcolemmal LDs is 524 
larger in type 2 fibers than in type 1 fibers. E: The number of intermyofibrillar LDs is higher in type 525 
1 fibers than in type 2 fibers. F: The number of subsarcolemmal LDs is higher in type 1 fibers than 526 
in type 2 fibers. **** P < 0.0001. *** P < 0.001. ** P < 0.01.  In A-H, n = 29 subjects.  527 
Figure 4. Histograms of LD diameter in type 1 and 2 human skeletal muscle fibers at baseline. 528 
The total number of measured LDs were 1560 and 697 in the intermyofibrillar space of type 1 and 2 529 
25 
 
fibers, respectively, and 669 and 512 in the subsarcolemmal space of type 1 and 2 fibers, 530 
respectively.    531 
Figure 5. Volume fractions of LDs in distinct locations of human muscle fibers: Effects of 532 
endurance training, ESA treatment, or a combination hereof. A-D: No combined or main 533 
effects on volume fractions of intermyofibrillar or subsarcolemmal LDs in type 1 fibers or type 2 534 
fibers. E-F: Training mediated an increase in the relative fraction of the LDs, that are located in the 535 
intermyofibrillar region of type 1 fibers * P < 0.05. n = 6, 9, 7, 8, 8, 10, 8, 7 subjects (from left to 536 
right). SP: sedentary-placebo, SE: sedentary-ESA, TP: training-placebo, TE: training-ESA. 537 
Figure 6. Size and number of LDs in distinct locations of human muscle fibers. Effects of 538 
endurance training, ESA treatment, or a combination hereof. A-B: No combined or main effects 539 
on the size of individual intermyofibrillar LDs in type 1 fibers or type 2 fibers. C-D: Training 540 
mediated a decrease in the size of individual subsarcolemmal LDs in type 2 fibers. E-F: EPO 541 
mediated a decrease in the number of intermyofibrillar LDs in type 1 fibers. G-H: EPO mediated a 542 
decrease in the number of subsarcolemmal LDs in type 1 fibers. *** P < 0.001.  ** P < 0.01. n = 6, 543 
9, 7, 8, 8, 10, 8, 7 subjects (from left to right). SP: sedentary-placebo, SE: sedentary-ESA, TP: 544 
training-placebo, TE: training-ESA.  545 
Figure 7. Histograms of intermyofibrillar and subsarcolemmal LD diameter in human 546 
skeletal muscle fibers before and after endurance training. The total number of measured 547 
intermyofibrillar LDs were 817 and 1446 in type 1 fibers pre- and post-training, respectively, and 548 
394 and 554 in type 2 fibers pre- and post-training, respectively The total number of measured 549 
subsarcolemmal LDs were 379 and 474 in type 1 fibers pre- and post-training, respectively, and 299 550 
and 248 in type 2 fibers pre- and post-training, respectively. 551 
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